Exploring the exosome-nanosome combinatorial platform as a novel, universal, and ideal nanoparticle-based drug delivery system

在研究实施的第一个财政年度，生产和分离得到了优化，以产生大量的外切体。这一部分对于“纳米体”的整合是重要的，因为要生产的“外显体-纳米体”平台的数量取决于所产生的外显体。喂养和饥饿的细胞之间产生的外切体的数量也被确定为不同的。一些外体蛋白在饥饿状态下表达下调。这些都非常重要，因为不同细胞/器官上的“外切体-纳米小体”的整合也会受到显著的影响。平台的构建显示出对“纳米小体”的整合存在局限性，优化(大小、配体组成和总电荷)似乎是必要的。

During the first fiscal year of research implementation, production and isolation have been optimized to yield high number of exosomes. This part is important for the incorporation of "nanosome" as the number of "exosome-nanosome" platform to be produced is dependent on the produced exosomes. The amount of exosome produced between fed and starved cells were also determined to be different. Some exosome proteins are downregulated in the starved state. These are significantly important as the "exosome-nanosome" incorporation on different cells/organs can also be impacted significantly.The construction of the platform showed limitations on the incorporation of the "nanosome" and optimization (sizes, ligand composition, and the overall charge) seemed to be necessary.